Just now! The Healthcare Security Administration ordered: comprehensive monitoring of consumables centralized procurement
From quantity reporting, procurement, distribution to use, the supervision of the “post-cycle” of the centralized procurement has begun to fully land!
The Healthcare Security Administration ordered: comprehensive monitoring of consumables centralized procurement
Just yesterday afternoon (June 5th), the Qinghai Provincial Healthcare Security Administration issued the Notice on Strengthening the Implementation of the Selection Results of Centralized Volume Procurement of Drugs and Medical Consumables (hereinafter referred to as the Notice ).
The Notice clearly states that the implementation of centralized procurement and selection results by public medical institutions should be monitored with a full process, full cycle, and refined system management thinking. The monitoring work should be reported in writing to the provincial Healthcare Security Administration every six months (June and December), forming a regular monitoring, hierarchical response, upper and lower linkage, and collaborative and efficient work mechanism at the provincial and municipal (state) levels to ensure accurate reporting, sufficient supply, and actual usage of selected products in centralized procurement!
This means that the supervision of the “post link” of medical consumables centralized procurement has begun to fully land! The precision and real-time monitoring of the big data of the unified platform will cover the whole process of reporting volume, procurement, distribution and use, and the violation of the amount of hospital procurement, the supply stop of mechanical enterprises and the distribution of substandard products will be found in the first time and more stringent penalties will be implemented!
Hospital consumables centralized procurement, all-round monitoring!
First of all, at the hospital side, the monitoring of volume self-reporting link will be started .
The document requires medical institutions to determine the amount of procurement accurately and reasonably in combination with historical actual use, clinical feedback, medical technology progress and other factors.
Medical institutions that “use but do not report” and report a large difference between the amount and the historical purchase amount (more than 20% less than the actual purchase amount of the previous year) are required to carry out an audit or make an explanation at the report stage; In the process of implementation, the products with abnormal amounts are monitored.
In the implementation link, the Notice emphasizes that medical institutions give priority to the use of selected products, and strictly implement the selected results of centralized procurement. Medical institutions that “use without reporting”, purchase a large number of non-selected consumables or alternative consumables, and fail to complete the agreed amount of procurement are included in the scope of key supervision.
At the same time, strict monthly monitoring, quarterly notification, and rectification and disciplinary measures are implemented!
Monthly monitoring
The centralized procurement platform will be fully mobilized to monitor the implementation of the selected results by public medical institutions on a regular and detailed basis, establish “one hospital, one file”, and monitor the procurement and use of selected products by project, batch and species in public medical institutions in the region on a monthly basis, so as to keep abreast of the progress of completion of the agreed procurement volume of medical institutions, sequential procurement progress of the procurement and use of the selected products and non-selected products.
The third month, a thorough investigation
From the third month after the implementation of the selected results, a round of investigation and sorting should be carried out on the admission and use of selected products in public medical institutions in the region.
Discontinued supply, substandard distribution, discontinued and banned from the market!
In the pharmaceutical enterprise side, the monitoring is mainly focused on product quality, supply and distribution.
If the selected enterprise has the following problems, it will be replaced by alternative products, be included in the blacklist of dishonesty punishment, and cancel the distribution qualification of severe punishment!
01
For medical enterprises that cannot meet the procurement needs of medical institutions in a timely manner and do not supply according to the agreement, the provincial Healthcare Security Administration shall give corresponding grade credit evaluation according to the circumstances, and timely start the supply of alternative products.
02
Selected products in the procurement cycle, found quality problems, timely feedback to the drug regulatory department, and reported to the provincial medical insurance bureau for the record, start the supply of alternative products. During the procurement cycle of the selected product, if any quality issues are found, timely feedback should be provided to the drug regulatory department and reported to the provincial medical insurance bureau for record keeping to initiate the supply of alternative products.
03
The provincial Healthcare Security Administration shall notify and inquire enterprises with a delivery rate of less than 80% on a monthly basis. Enterprises with a delivery rate of less than 80% for three consecutive months shall be disqualified from distribution throughout the province.
Earlier (February 16), in the centralized procurement of intraocular lenses in Shanghai, ，Singclean Medical gave up the qualification for no reason and was included in the list of violations. In the next three years, all intraocular lens products and other new consumables of this enterprise will not be available for sale in Shanghai.
It can be said that after the establishment of the disciplinary mechanism, a large number of selected enterprises that do not meet the standards and do not supply will face stricter and more accurate supervision and punishment by the Healthcare Security Administration.
The Healthcare Security Administration: Comprehensive monitoring of the “post procurement stage” of centralized procurement
In fact, comprehensive monitoring of the centralized procurement of consumables has been included in the national key plan for this year since the beginning of the year.
On March 2nd, the National Healthcare Security Administration issued a Notice on Doing a Good Job in the Centralized Procurement and Price Management of Medicine in 2023. In addition to clarifying the variety and direction of medical consumables in volume procurement in 2023, it is also clear that 2023 will focus on the “post stage” of centralized procurement and initiate comprehensive monitoring.
After the document was issued, on April 10, Shandong Province took the lead in landing, fully relying on the national unified medical security information platform drug and medical consumables recruitment subsystem, and fully carrying out the whole process supervision of purchasing drugs and consumables with quantity.
China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
Source：Medical Device Distributors Alliance
Translated & edited ： Bradyknows
